Document Detail

Current and future trends in the oral pharmacotherapy of male erectile dysfunction.
MedLine Citation:
PMID:  12943496     Owner:  NLM     Status:  MEDLINE    
The promising clinical data on the use of the first orally active phosphodiesterase inhibitor sildenafil citrate (Viagra) for treatment of male erectile dysfunction have been accompanied by an increase in research activities on the physiology of the male erectile mechanism. This included both peripheral intracellular signal transduction in the corpus cavernosum as well as central brain and spinal cord pathways that control penile erection. This work provided the basis for the development and introduction of several new therapeutic modalities into the management of erectile dysfunction that is now offered to the patients. Since the concept of 'taking a pill' as a cure for an illness or the relief of symptoms of a disease has become widely accepted by consumers, the pharmacological treatment of erectile dysfunction has primarily focused on selective, orally available drugs that act via influencing intracellular or central regulatory mechanisms, combining a high response rate and the advantage of an 'on-demand' intake. These agents are regarded as more efficacious, have a faster onset of drug action in the target tissue and an improved effect-to-side effect ratio than sildenafil. The purpose of this review is to describe the major novel and evolving pharmacological advances in the field of oral pharmacotherapy for the treatment of male erectile dysfunction.
Stefan Uckert; Christian G Stief; Udo Jonas
Related Documents :
989356 - Pharmacological studies on a new 1-benzoyloxy-alkylaminocycloalkane derivative (yau-17)...
16326816 - Transient inhibition of cyp3a in rats by star fruit juice.
3516886 - The role of the prosthodontist in the treatment of periodontal disease.
17468716 - Oral aphthous-like ulceration due to tiotropium bromide.
2405676 - Controlling refractory atonic postpartum hemorrhage with hemabate sterile solution.
23030006 - Temperature-sensitive polymer-coated magnetic nanoparticles as a potential drug deliver...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  12     ISSN:  1354-3784     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-08-28     Completed Date:  2004-01-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1521-33     Citation Subset:  IM    
Hannover Medical School, Department of Urology, 30625 Hannover, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Adrenergic alpha-Antagonists / administration & dosage,  pharmacology,  therapeutic use
Dopamine Agents / administration & dosage,  pharmacology,  therapeutic use*
Drug Design
Enzyme Activators / administration & dosage,  pharmacology,  therapeutic use
Erectile Dysfunction / drug therapy*
Human Growth Hormone / administration & dosage,  pharmacology,  therapeutic use
Phosphodiesterase Inhibitors / administration & dosage,  pharmacology,  therapeutic use
Receptors, Melanocortin / agonists
Serotonin Antagonists / administration & dosage,  pharmacology,  therapeutic use
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Dopamine Agents; 0/Enzyme Activators; 0/Phosphodiesterase Inhibitors; 0/Receptors, Melanocortin; 0/Serotonin Antagonists; 12629-01-5/Human Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and T...
Next Document:  Prevention of perinatal HIV transmission: a review of novel strategies.